Xueqiong Zhang

Xueqiong Zhang

Auto-generated profile, based on publicly available information

Xueqiong Zhang

School of Chemistry, Chemical Engineering and life sciences, Wuhan University of Technology, Wuhan, China

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2020 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
MJMin Jiang
Min Jiang
KHKaiyong He
Kaiyong He
TQTong Qiu
Tong Qiu
JSJiahui Sun
Jiahui Sun
QLQi Liu
Qi Liu
HZHua Zheng
Hua Zheng

1 January 2012 in The American Journal of Chinese Medicine
Verified
Journal Article
Closed access
XZXue-Qiong Zhang
Xue-Qiong Zhang
JKJin-Hwa Kim
Jin-Hwa Kim
GLGeun-Soo Lee
Geun-Soo Lee
HPHyeong-Bae Pyo
Hyeong-Bae Pyo
ESEun-Young Shin
Eun-Young Shin
Yong-He ZhangYong-He Zhang
Yong-He Zhang

10 February 2021 in Nanotechnology
Verified
Journal Article
Closed access
PDF file
MTMingxiu Tang
Mingxiu Tang
MYMengjia Yang
Mengjia Yang
KHKaiyong He
Kaiyong He
RLRan Li
Ran Li
XCXiaojie Chen
Xiaojie Chen
TQTong Qiu
Tong Qiu
We aimed to combine glycyrrhetinic acid with doxorubicin to prepare, characterize and evaluate a drug delivery nano-system with REDOX sensitivity for the treatment of breast cancer. M-DOX-GA NPs prepared by nano sedimentation were spherical, with a particle size of 181 nm. And the maximum encapsulation efficiency and drug loading in M-DOX-GA NPs were 89.28% and 18.22%, respectively. Cytotoxicity and cellular uptake experiments of nanoparticles to KC cells, Cal-27 cells and 4T1 cells were studied by the CCK-8 method. The result indicated that M-DOX-GA NPs could accurately release the drug into the tumor cells, thus achieving the targeted release of the drug. Comparing the survival rate of the above three cells, it was found that M-DOX-GA NPs had a good tumor selectivity and had a more significant therapeutic effect on breast cancer. A 4T1-bearing mouse model was established, and the tumor inhibition rate was 77.37% after injection of nanoparticle solution for 14 d. Normal tissue H&E stained sections and TUNEL assay were verified M-DOX-GA NPs have excellent tumor suppressive effect, and can efficiently reduce the toxic side effects on normal organisms, and effectively avoided 4T1 cells metastasis. Immunofluorescence detection and Western-blot analysis figured a decline in both CUGBP1 and α -SMA, which verifying the TME remodeling induced by glycyrrhetinic acid. Collectively, the combination of doxorubicin and glycyrrhetinic acid is an effective and safe strategy for remodeling fibrotic TME by improving the therapeutic outcome for breast cancer.

13 April 2016 in Journal of Wuhan University of Technology-Mater. Sci. Ed.
Verified
Journal Article
Closed access
PDF file
ZHZhengyu Hu
Zhengyu Hu
HZHua Zheng
Hua Zheng
DLDan Li
Dan Li
XXXiong Xiong
Xiong Xiong
MTMingyuan Tan
Mingyuan Tan
HYHan Yan
Han Yan

3 August 2015 in Acta Pharmacologica Sinica
Verified
Journal Article
Open access
PDF file
ZSZhao-Fu Sheng
Zhao-Fu Sheng
XCXiang-Yu Cui
Xiang-Yu Cui
SCSu-Ying Cui
Su-Ying Cui
BYBin Yu
Bin Yu
XZXue-Qiong Zhang
Xue-Qiong Zhang
Yong-He ZhangYong-He Zhang
Yong-He Zhang
Aim: 7-O-ethylfangchinoline (YH-200) is a bisbenzylisoquinoline derivative. The aim of this study was to investigate the antidepressant-like action and underlying mechanisms of YH-200 in mice. Methods: Mice were treated with YH-200 (15, 30, and 60 mg/kg, ig) or tetrandrine (30 and 60 mg/kg, ig) before conducting forced swimming test (FST), tail suspension test (TST), or open field test (OFT). Results: YH-200 (60 mg/kg) significantly decreased the immobility time in both FST and TST, and prolonged the latency to immobility in FST. YH-200 (60 mg/kg) was more potent than the natural bisbenzylisoquinoline alkaloid tetrandrine (60 mg/kg) in FST. Pretreatment with α1-adrenoceptor antagonist prazosin (1 mg/kg), β-adrenoceptor antagonist propranolol (2 mg/kg), dopamine D1/D5 receptor antagonist SCH23390 (0.05 mg/kg), dopamine D2/D3 receptor antagonist haloperidol (0.2 mg/kg) or AMPA receptor antagonist NBQX (10 mg/kg) prevented the antidepressant-like action of YH-200 (60 mg/kg) in FST. In contrast, pretreatment with α2 adrenoceptor antagonist yohimbine (1 mg/kg) augmented the antidepressant-like action of YH-200 (30 mg/kg) in FST. Chronic administration of YH-200 (30 and 60 mg/kg for 14 d) did not produce drug tolerance; instead its antidepressant-like action was strengthened. Chronic administration of YH-200 did not affect the body weight of mice compared to control mice. Conclusion: YH-200 exerts its antidepressant-like action in mice via acting at multi-targets, including α1, α2 and β-adrenoceptors, D1/D5 and D2 /D3 receptors, as well as AMPA receptors.

15 March 2022 in Nanotechnology
Verified
Journal Article
Closed access
MYMengjia Yang
Mengjia Yang
XLXiaojun Lv
Xiaojun Lv
SZSiwen Zhan
Siwen Zhan
MLMengli Lu
Mengli Lu
XZXueqiong Zhang
Xueqiong Zhang
TQTong Qiu
Tong Qiu
We combined phosphoinositol-3-kinin inhibitor IPI-549 and photodynamic Chlorin e6 (Ce6) on carboxymethyl chitosan to develop a novel drug delivery nanoparticle (NP) system (Ce6/CMCS-DSP-IPI549) and evaluate its glutathione (GSH) sensitivity and targeting ability for breast cancer treatment. The NPs were spherical with a uniform size of 218.8 nm, a stable structure over 7 days. The maximum encapsulation efficiency was 64.42%, and NPs drug loading was 8.05%. The NPs released drugs within tumor cells due to their high GSH concentration, while they maintained structural integrity in normal cells, which have low GSH concentration. The cumulative release rates of IPI-549 and Ce6 at 108 h were 70.67% and 40.35% (at GSH 10 mM) and 8.11% and 2.71% (at GSH 2 μ M), respectively. The NPs showed a strong inhibitory effect on 4T1 cells yet did not affect human umbilical vein endothelial cells (HUVECs). After irradiation by a 660 nm infrared laser for 72 h, the survival rate of 4T1 cells was 15.51%. Cellular uptake studies indicated that the NPs could accurately release drugs into tumor cells. In addition, the NPs had a good photodynamic effect and promoted the release of reactive oxygen species to damage tumor cells. Overall, the combination therapy of IPI-549 and Ce6 is safe and effective, and may provide a new avenue for the treatment of breast cancer.